We use cookies to give you the best experience possible with our website and to improve our communication with you. We consider your selection and will only use the data you have approved us to gather.

These cookies help making a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.

These cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously. With this information we can constantly improve the experience we offer on our website.

These cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.

News at Geistlich Pharma AG

2021 · 2020 · 2019 · 2018 · 2017 · 2016 · 2015 · 2014 · 2013 ·
  • Since 26 May 2021, the new and stricter legislation for the market authorization of medical devices in the EU, the Medical Device Regulation (MDR), has been in force. Geistlich Pharma obtained the first MDR certificates in August 2021, both for the quality management system and for the first product family, Geistlich Fibro-Gide®. This paves the way for continued market access of all Geistlich Pharma products in the EU. Nicole Guetg, Senior Regulatory Affairs Manager, and Reinhart Seibl, Director Regulatory Affairs, discuss the background.

  • In the festive setting of the event organised by the Chamber of Industry and Commerce of Central Switzerland (ihz), Geistlich CEO Ralf P. Halbach and his team accept the Innovation Recognition Award for Geistlich Derma-Gide®.

  • Geistlich Pharma has been working successfully with Meta, the medical technology division of C.G.M. S.p.A., for many years. With the acquisition of Meta Technologies S.r.l., Geistlich Pharma is expanding its existing offering as a regeneration specialist by adding a further recognized brand. Meta Technologies S.r.l. will continue its business relationships independently

  • Geistlich Pharma obtains 510(k) clearance from the US Food and Drug Administration (FDA) for its latest product Geistlich Nexo-Gide®. It will be presented at surgical podiatry and orthopaedic congresses in Florida and Nevada from November 2021. For patients with severe tendon and ligament injuries, the collagen membrane increases the likelihood of successful surgical procedures.

  • Geistlich Pharma wins the Innovation Recognition Award for the medical device Geistlich Derma-Gide®. Launched on the US market in 2019, the product particularly supports the healing process of foot ulcers that occur as a late consequence of diabetes. The novel wound matrix is an innovation that was developed 100% in Central Switzerland, is produced here.

  • Five questions for Friedrich Buck, who is responsible for Geistlich's "Scientific Education" with his team. He himself is a dentist with many years of experience. What current topics are driving him and what dental education offers should you be aware of following the pandemic?

  • Geistlich Pharma's Surgery business unit becomes the exclusive distribution partner for the NUsurface® meniscus implant in Switzerland and enters into an exclusive partnership with Active Implants. The objective of both companies is to support pain patients by preserving joints.

  • Last weekend Geistlich once again called for the "Geistlich Charity Walk & Run". The employees came in droves: Participants around the world ran for a donation of 20,955 US dollars. This will benefit a children's dental project in China.

  • This summer, three apprentices at Geistlich successfully obtained their Swiss Federal Certificate of Competence (EFZ). We are proud and congratulate them!

  • Having started at Geistlich from the beginning of 2021, Dr. Ralf Halbach took the helm as CEO from July. We review his first few months in the company and hazard a guess at what might be expected for Geistlich in the future. Five questions for the new CEO.

PRESS CONTACT
Dr. Mirjam Kessler
Director Corporate Communications